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Abstract
Many statistical methods have been developed to screen for differentially expressed genes
associated with specific phenotypes in the microarray data. However, it remains a major challenge
to synthesize the observed expression patterns with abundant biological knowledge for more
complete understanding of the biological functions among genes. Various methods including
clustering analysis on genes, neural network, Bayesian network and pathway analysis have been
developed toward this goal. In most of these procedures, the activation and inhibition relationships
among genes have hardly been utilized in the modeling steps. We propose two novel Bayesian
models to integrate the microarray data with the putative pathway structures obtained from the
KEGG database and the directional gene–gene interactions in the medical literature. We define the
symmetric Kullback–Leibler divergence of a pathway, and use it to identify the pathway(s) most
supported by the microarray data. Monte Carlo Markov Chain sampling algorithm is given for
posterior computation in the hierarchical model. The proposed method is shown to select the most
supported pathway in an illustrative example. Finally, we apply the methodology to a real
microarray data set to understand the gene expression profile of osteoblast lineage at defined
stages of differentiation. We observe that our method correctly identifies the pathways that are
reported to play essential roles in modulating bone mass.
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1 Introduction
Genome informatics was born to cope with the vast amount of data generated by the
genomic studies, in particular, to support experimental projects. The challenges for post-
genome informatics are on synthesis of biological knowledge from genomic information
toward understanding of general principles of life. So post-genome informatics has to be
coupled with systematic experiments in functional genomics. However, the coupling is in a
different direction where informatics plays a dominant role in designing experiments and
prediction.
High-throughput gene analysis technology such as cDNA microarray and oligonucleotide
arrays has enabled parallel analysis of thousands of genes simultaneously. Numerous
statistical methods have been developed to screen for differentially expressed genes, either
up- or down-regulated, in these experiments. While these projects rapidly determine gene
catalogs for an increasing number of organisms, functional annotation of individual genes is
still largely incomplete. It would be essential to have knowledge on coregulated genes and
their interactions. Consequently, various methods have been developed toward these goals.
The methods include clustering analysis on genes, neural network, Bayesian network (BN),
and pathway analysis. In this paper, we will focus on pathway and Bayesian network
approaches.
There are multiple sources of knowledge on pathway and gene interaction. Kyoto
Encyclopedia of Genes and Genomes (KEGG) database [17] was initiated by Japanese
human genome program in 1995 to link genomic information with higher order functional
information by computerizing current knowledge on cellular processes and by standardizing
gene annotations. These databases are often called meta-data, which means data about data.
KEGG consists of three databases: PATHWAY for representing higher order functions in
terms of the network of interacting molecules, GENES for the collection of gene catalogs for
all completely sequenced genomes and some partial genomes, and LIGAND for the
collection of chemical compounds in the cell, enzyme molecules and enzymatic reactions. A
pathway is a collection of graphical diagrams of interacting molecules obtained from many
years of intensive biomedical research representing the present knowledge on various
cellular or physiologic functions. It is supposed to be a computer representation of the
biological system, so it can be used as part of the systems biology approach.
In addition to KEGG, such databases also include gene ontology (GO) database (Gene
Ontology Consortium, 2001), and BioCarta (www.biocarta.com). We are focusing on the
KEGG pathway database because it contains the directional relationship (activation or
inhibition) between genes that is extremely useful in the system biology approach.
Moreover, it provides a rich set of possible structures on the gene to gene relationships. The
KEGG pathway can be expanded to a general pathway database to include recently
developed and published pathways.
Another valuable source of biological knowledge is the gene-to-gene activation or inhibition
knowledge aggregated from past experiments or literature search. We deposit these
directional relationships among genes in a database called PrimeDB. So from this database,
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we can search for evidence of gene-to-gene activation or inhibition measured by the number
of journals reporting these interactions.
Our goal is to investigate gene to gene interactions by integrating the following three
components: the structure information of putative pathways available from pathway
networks, the gene relations uncovered by literature mining as in PrimeDB and the
microarray gene expression data. The first two components can be obtained before the
microarray experiments, so we consider them as prior information. We will describe how we
could revise our prior opinion on pathway after seeing the microarray results using Bayesian
methods. Moreover, we develop methods for ranking pathways in terms of their degree of
agreement with the microarray data. Figure 1 provides a schematic summary of the database
integration.
Current statistics methods on pathway activities are mostly in the area of gene set
enrichment analysis (GSEA) where a set of regulated genes in a pathway are compared to
the regulated gene set in the microarray studies to determine whether the set is particular
enriched by the pathway. Curtis et al. [3] have provided a table of software, annotation, and
statistical methods used in each software. In general, Gene ontology (GO), GenMapp,
KEGG, and Biocarta have been used for the annotations. Efron and Tibshirani [4] and
Newton et al. [23] have provided more improved methods for gene enrichment analysis.
However, all these methods are restricted to counting methods where the number of
regulated genes is counted in each pathway. They have not incorporated the putative
information on activation and inhibition relationships given in the KEGG database and
PrimeDB.
There are also several Bayesian papers studying pathways or networks. Friedman et al. [7]
propose an adaptive iterative search algorithm for an optimal Bayesian network (BN) while
search is restricted to the most promising candidate parents of each gene based on some
local statistics (such as correlation). Their learning algorithm uses no prior biological
knowledge nor constraints. Hartemink et al. [10] extend the BN by adding edge annotation,
which allows representation of additional information about the dependence relationships
among genes. Sachs et al. [24] outline modeling the cell signaling pathways using BN.
Sebastiani et al. [25] show the application of BN to the analysis of various types of genomic
data including genomic markers and gene expression data. They also introduce the
Generalized Gamma Networks to depict the possibly nonlinear parent–child dependencies.
Werhli and Husmeier [29] use Bayesian networks to reconstruct gene regulatory network by
integrating microarray data and multiple sources of prior knowledge such as KEGG
pathways and promoter motifs. The prior probability of a network is modeled by a Gibb
distribution, in which each source is encoded by a separate energy function. Shen and West
[26] develop probability pathway annotation (PROPA) to match outcomes in gene
expression to multiple biological pathway gene sets from curated databases. Monni and Li
[22] show how to utilize the prior genetic pathway and network information in the analysis
of genomic data in order to obtain a more interpretable list of genes that are associated with
the genotypes. Ellis and Wong [5] have examined computational algorithms for determining
BN structures from experimental data. However, as far as we know, the activation and
inhibition relationships among genes have hardly been utilized in the modeling steps of
these procedures, except Ellis and Wong.
In this paper, we consider the pathways given in KEGG as possible models. Each pathway is
a weighted graph that includes the activation and inhibition binary relationships. Given our
microarray data, we are interested in knowing which pathway, or a set of pathways are most
agreeable to our microarray experiment results. In the frame work of model selection, we are
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essentially asking which pathway is most supported by the microarray data. Instead of the
best one, we can also select a few pathways that are most supported by the data.
Our approach considers the results of microarray analysis as data. So we start with the
selected regulated (significant) gene list from microarray analysis. The outcome for each
selected genes is modeled as a discrete random variable taking values of 1 and 0,
representing up-regulated and down-regulated, respectively. Then we consider a set of
putative pathways (say 80 for example) from KEGG that needs to be studied. We first
modify them slightly so each pathway can be considered as a BN with a directed acyclic
graph. Then for each pathway structure in the set, we write down the local prior distribution
for each node in the pathway. The hyperparameters in the prior information representing not
only the propensities for a gene to have an activation or an inhibition effect on other genes,
but also indicating the strength of this prior belief. They may have a big influence on the
decision making of ranking pathways. So the formulations of them are guided by the
PrimeDB which are being constructed by the informatics group of the authors here. We
propose two possible solutions to the choice of hyperparameters: (A) Use the prior
information obtained from PrimeDB to formulate good estimates of these hyperparameters.
Then we just plug in these estimates for the hyperparameters. (B) Treat these
hyperparameters as random variables to build another layer of hierarchial model sensibly
guided by the PrimeDB and to achieve more robust results. We will develop both methods
and examine their effects. We update these local distributions from KEGG and PrimeDB
information conditioning on the data using the Bayes theorem. Then we rank the pathways
by using the symmetric Kullback–Leibler divergence [19]. The most likely pathway has the
smallest symmetric Kullback–Leibler divergence between the prior and the posterior
distributions. We also extend our methodology to include all the genes in the microarray as
data as given in Sect. 5.
This rest of this paper is organized as follows: Sect. 2 describes the simple Bayesian model
which uses PrimeDB to specify prior directly, and defines the symmetric Kullback–Leibler
divergence to measure pathway activities; Sect. 3 extends this divergence measure to the
multilevel model, in which the second level prior governs our prior belief on the activation
or inhibition effect aggregated by PrimeDB, A Markov chain Monte Carlo (MCMC)
algorithm is proposed for posterior estimates computation; Sect. 4 demonstrates our method
with a simple example, and Sect. 5 evaluates model performance through an osteoblast
microarray study. We conclude the paper with a brief discussion in Sect. 6.
2 Simple Bayesian Model Using PrimeDB Directly
The easiest way to represent a network is to use a graph, which is a collection of vertices
(nodes) and edges that connect vertices. The vertices can be genes, transcription factors,
proteins, ligands, etc. All vertices need not be connected in a graph. A directed graph has
one-way edges (arcs) that can represent an irreversible molecular reaction. In a weighted
graph, weights (costs) are assigned to the edges, for example to distinguish between
activation and inhibition in a signal transduction pathway.
We will first treat a pathway as a BN. A BN comprises two components: a directed acyclic
graph (DAG) and a probability distribution. It is a graph with no path that starts and ends at
the same node. The nodes in DAG depict stochastic variables. So the node can represent the
outcome of a gene after a microarray experiment. The arcs in the DAG display directed
dependencies among variables that are quantified by conditional probability distributions.
Lack of arcs between two nodes indicates conditional independence. Heckerman [11]
provides an excellent tutorial on the BN. We are highlighting the key points here.
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Let Y = (Y1, . . . , YQ) denote the outcomes of Q nodes in a BN. A BN consists of:
1. a network structure S that encodes a set of conditional independence assertions
about the variables in Y;
2. a set of local probability distributions associated with each node.
In our application of BN on pathways, S comprises not only the set of conditional
independence assertions among genes, but also the activation and inhibition effect among
them. Note that in model derivation, we focus on the pathways in which each gene has a
single parent, either activator or inhibitor. We also restrict our attention to a binary BN,
where for each variable yi takes on only two values, with yi = 1, 0 for representing gene i
being up- or down-regulated, respectively. In Sect. 5, we demonstrate that our model is
readily extended to pathways which consist of equivalently expressed genes and/or genes
with multiple parents.
2.1 Notations and Transition Probabilities
We classify a gene in a pathway into three categories: (1) with no parents, (2) with an
activator parent, and (3) with an inhibitor parent. In particular, we have the following
notations for the three categories:
: the index set of genes
without parents.
: the index set of
genes with Activator parents in a pathway of Q genes.
: the index set of
genes with Inhibitor parents in a pathway of Q genes.
We use  to denote the probability of gene i being up-regulated, for . Given we assume
a gene can be either up- or down-regulated, so a Bernoulli distribution with probability 
suffices to model this outcome. We use  to describe the set of initial states of a
pathway, that is, for the gene(s) without parents.
For genes with parents, we need to define their transition probabilities. Let Yi denote the
outcome for gi with its parent to be gj. Use symbols ∪ for being up-regulated, and ∩ being
down-regulated. Then we define the transition probabilities for the connected genes as in
Tables 1 and 2. That is: If gj activates gi, then we assume
. Consequently,
. If gj inhibits gi, then we assume
. Consequently,
. Observe that θi|j represents an activation effect
and ϕi|j an inhibition effect from gene j to i. So the transition probabilities define the local
distribution of each node (gene) in the pathway, which is a collection of Bernoulli
distributions. Observe if we let ϕi|j = 1 – θi|j, then can collapse Tables 1 and 2 into one table.
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Let  be the parameter vector of pathway S, where  is the vector
of up-regulated genes with no parents, and  and  are the
vectors of transition probabilities for genes being activated and inhibited, respectively. Let D
denote the data, which are assumed to be a random sample from the joint distribution of Y.
So D consists of (1) n, the total number of microarray experiments being analyzed, (2) n̄i,
the count for being up-regulated in n experiments for each , and (3) ni|j denotes the
number of concordant pairs (( ) or ( )) for gene j and gene i ordered pair in n
experiments where gene j is a parent, and gene . If gene , then nij denotes the
number of discordant pairs (( ) or ( )) for the gene j and gene i pair. By the local
Markov property of the BN which says that each node is independent of its non-descendants
given the parent nodes, the likelihood function, L(θs|D), of a given pathway S is the product
of the local distributions over all the genes in it. It is given as
2.2 Prior Elicitation and the Posterior Distributions
Suppose in the PrimeDB, there are ai|j journal articles citing that gj activates gi and bi|j
journal articles citing gj inhibits gi. To incorporate these prior information, we would first
assume Simple Bayesian model using PrimeDB directly. We assume θi|j ~ βe(ai|j, bi|j) for the
activation effect, and ϕi|j ~ βe(bi|j, ai|j) for the inhibition effect. If PrimeDB does not provide
information on the initial state, we can use a vague prior for it, for example, .
Assuming that the parameters are mutually independent over i, the joint prior distribution
can be written as:
(2.1)
Assuming there are no missing data, i.e., for each node in the BN we observe some data, the
posterior distribution π(θs|D, S) is then given as:
(2.2)
So it is obtained by updating the local posterior distributions of θi|j or ϕi|j. Suppose that
KEGG suggests that gj activates gi, we need to update θi|j given the data. So we count the
number (denoted by ni|j) of ordered pairs with outcomes to be ∪ to ∪ or ∩ to ∩ from gj to gi.
It is actually the number of concordant pairs for the of (gj, gi). The number of discordant
pairs with ∪ to ∩ or ∩ to ∪ is n – ni|j . So the distribution of θi|j given data is updated toβe(ai|j + ni|j, bi|j + n – ni|j). Similarly, if KEGG suggests that gj inhibits gi, the posterior
distribution of ϕi|j given data is βe(bi|j + ni|j, ai|j + n – ni|j).
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2.3 Selection Criterion of Supported Pathways: Symmetric Kullback–Leibler Divergence
We propose to use the symmetric Kullback–Leibler divergence [19] to select the best
pathway. The smaller symmetric Kullback–Leibler divergence between the prior and
posterior distributions of a given pathway, the more supported by the data this pathway is.
The Kullback–Leibler (KL) divergence is conventionally used to measure the difference
between two densities. The KL divergence of the probability distribution f1(y) from f2(y) is
defined as
We highlight the key properties of KL divergence as follows. First, the KL divergence is not
a distance because it is asymmetric, i.e., KL(f1, f2) ≠ KL(f2, f1), and it does not satisfy the
triangle inequality. Second, using Jensen's inequality, it can be shown that the KL
divergence is nonnegative if f2 is a proper density, and equals zero if and only if f1 = f2.
Third, the KL divergence measures how much information f2 carries about f1, if f1 is
considered the “true” distribution of the data.
For more intuitive interpretation, we adopt the definition of the symmetric KL divergence
introduced by Kullback and Leibler (1951)
Let us first define the symmetric KL divergence of gene i in the simple model as:
(2.3)
where
and p(yi|pai, γi, S) is the local probability distribution for gene i, and pai denotes the
configuration of its parent. Note that in our single-parent pathways, it can be an empty set or
a singleton set having parent gene j. Equation (2.3) is an immediate consequence of the fact
that π(γi|S) is a proper prior and its normalized constant is 1.
Because different pathways have different gene sizes, we use the geometric mean of the
symmetric KL divergence for individual genes to correct for different dimensions. We thus
define the symmetric KL divergence of a pathway S with Q genes as
(2.4)
Let π*(θs|S) be the kernel density of the prior, and let C0(S) and CD(S) be the normalizing
constants of prior and posterior distributions, respectively. We can write
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Then (2.4) becomes
(2.5)
after canceling out ln(CD(S)/C0(S)) and ln(C0(S)/CD(S)) in the evaluation. This makes the
definition of the symmetric KL divergence more attractive, because the computation of
CD(S)/C0(S) can be very expensive.
By local Markov property of BN, the likelihood function, L(θs|D), is the product of the local
probability distributions. Moreover, as shown in (2.1) and (2.2), the prior distribution of
pathway S can also be decomposed into the product of local prior distributions of its
component genes, so can be the joint posterior distribution. Consequently, we have
Here θs(–γi) denotes the transition probability vector of pathway S without gene i's transition
probability γi. Note
Hence, the symmetric KL divergence of a pathway is the average of the symmetric KL
divergences of its component genes. This has sensible interpretation. When a pathway is
supported by the microarray data, we expect that, on average, the discrepancy between the
local conditional distributions of its genes and their prior distributions will be small. And so
will be the discrepancy between the local conditional distributions and the posterior
distributions, because the prior is part of the posterior.
Since the log likelihood breaks into the sum of three parts: the one of log local distributions
of initial states, of activated genes and of inhibited genes, we have
where
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and . To evaluate the I1, I2 and I3, we will make use of the following result.
Proposition 1 If Z ~ βe(α, β), and a, b > 0, then
where ψ(α) is the standard digamma function defined as
It is straightforward to verify the proposition by interchanging the order of integration (with
respect to z) and differentiation (with respect to α, β, or α + β). Consequently, we have
(2.6)
(2.7)
I3 is similar to I2 except ai|j is replaced by bi|j, and vice versa.
Hence, in the simple model, the computation of SKL(S) boils down to evaluating the sum of
a series of the difference of digamma functions, weighted by the gene size of the pathway.
Our average Q value attempts to adjust for the size of the pathways. In spite of the fact that
larger pathways would be less sensitive to a few extreme SKL scores on the gene level, it is
not necessary that the Q score always gives advantage to larger pathways.
3 Extension of the Symmetric KL Divergence to the Multilevel Model
3.1 Multilevel Model Guided by PrimeDB
An extra level of hierarchical Bayesian model can be constructed to allow information
sharing among the same types of gene, one for activation, the other for inhibition. We define
the first level prior distribution: for all i and j, θi|j|θ ~ βe(ai|j θ, bi|jθ), they are independent
over all i and j given θ. Similarly, ϕi|j|ϕ ~ βe(bi|jϕ, ai|jϕ) and are independent given ϕ. The
second level prior  is independent of  with known μ and ν, where 
denotes an exponential distribution with mean μ. By the way, it is possible to allow
unknown μ and ν, so we can build a third level to allow sharing between the types of gene.
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For the time being, we are only considering two levels with μ and ν known. Note the first
level specification yields E(θi|j|θ) = ai|j/(ai|j + bi|j). This is the same mean as in the Simple
Bayesian model. However Var(θi|j|θ) = ai|jbi|j/[(ai|j + bi|j)2(ai|jθ + bi|jθ + 1)]. So this
hierarchical model adds one more parameter θ that controls our prior belief of the PrimeDB.
The bigger the θ, the stronger the belief on the PrimeDB. Note that when μ = ν = 1, the
distributions of transition probabilities conditional on θ and ϕ are the same as in the simple
model. All genes with an activation effect suggested by KEGG share a common factor θ that
can be learned from the data and PrimeDB. Similar considerations apply to the inhibition
parameters.
3.2 Symmetric KL Divergence for Multilevel Model
We first extend the definitions of SKL(π(γi|S), π(γi|D, S)) and SKL(S) in the multilevel
model. Including the hyperparameters that govern our belief on the activation or inhibition
effect from PrimeDB, the parameter vector of pathway S becomes . Let
Then the definition of SKL for gene i given in (2.3) sustains. Explicitly, for activated genes
π(γi|D, S) = π(θi|j|θ, D, S)π(θ|D, S), and for inhibited genes π(γi|D, S) = π(ϕi|j|ϕ, D, S)π(ϕ|
D, S).
To generalize the definition of SKL(S) to the multilevel model, it is easy to see that we need
to modify (2.5) to
(3.1)
Following the same logic in deriving SKL(S) in the simple model, we can verify that in the
multilevel model,
Now, the joint prior distribution can be collapsed as
(3.2)
(3.3)
where (3.2) follows the facts that  does not depend on θ or ϕ,  is independent of ϕ, ϕs|ϕ
is independent of θ, θ and ϕ are independent. Both the assumptions of θi|j|θ being
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independent over i and j for , and ϕi|j|ϕ being independent over i and j for , yield
(3.3).
Similarly, Ithe joint posterior distribution can be collapsed as
Substituting the specific forms of log likelihood function, the collapsed prior and posterior
distributions into (3.1), we can rewrite SKL(S) as a sum of symmetric KL divergence for the
genes without parents, activated, and inhibited:
(3.4)
where
(3.5)
(3.6)
with
(3.7)
(3.8)
(3.9)
and
(3.10)
Equations (3.7)–(3.10) are direct results of Proposition 1. It is easy to observe that I1′ equals
to I1 that is given in the simple model, because  does not depend on θ or ϕ.
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Next, we derive the optimal form for numerically evaluating
Notice that
(3.11)
where c* is the normalizing constant for , the prior  is a
proper density, and,
Now we can write
and plug it into (3.11), it follows that
(3.12)
where
(3.13)
So the first term of I2′ in (3.5) can be expressed as
Likewise, the first term of I3′ in (3.6) can be written as
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Therefore, when we use Monte Carlo methods to numerically evaluate the integrals in I2′
and I3′, we sample from the prior distribution only, rather than sample from both prior and
posterior distribution of θ and ϕ. This greatly improves the efficiency of computing KL
divergence.
We now summarize the algorithm for calculating the symmetric KL divergence in the
multilevel model:
1. Draw θ(t) from , and draw independently ϕ(t) from , for t = 1, . . ., N.
2. I2′ is approximated by
and I3′ is approximated by
where , , , and  are given in (3.7), (3.8), (3.9), and (3.10),
and
3. I1′ can be directly calculated as
4.
.
Remark It is natural to generate two Monte Carlo (MC) samples from π(θ|S) to approximate
 for , so that one sample is used for computing
, while the other for . However, we generate only one
MC sample from π(θ|S) to compute ri1. Chen et al. [2] pointed out that the use of two MC
samples in obtaining the MC estimate of ri1 may not necessarily be more efficient than the
use of just one MC sample. They showed that the latter actually reduces the asymptotic
variance of the estimate.
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3.3 MCMC Algorithm for Sampling from the Posterior Distributions
To update the unknown parameters, we first know that the probabilities of initial states,
( ), do not depend on the hyperparameters θ and ϕ, so their posterior distributions are
βe(1 + n̄i, 1 + n – n̄i). Then we will employ Metropolis [21] within Gibbs sampling
algorithm to update the transition probabilities and hyperparameters ( ). Chen et al.
[1] provide more details on the algorithm. Using the collapsing technique in drawing the
Gibbs sampler proposed by Liu [20],
The last step results from conditional independence. Therefore, given the hyperparameters θ
and ϕ and data, we update the transition probabilities ( ) among genes by sampling from
the beta distributions. From (3.12) and (3.13), we know that π(θ|D, S) is proportional to
h1(θ)μe–μθ, and π(ϕ|D, S) is proportional to h2(ϕ)νe–νϕ, and they are independent. We use
the Metropolis–Hastings algorithm to sample from π(θ|D, S) and π(ϕ|D, S). The MCMC
algorithm to sample the posterior distribution can be implemented as follows:
Step 1. Generate θ and ϕ independently given the data using the Metropolis algorithm
having the following target densities:
and
Since θ > 0, the local Metropolis algorithm in this step is done by sampling ξ = log(θ)
instead of θ using the following steps:
1.1 Obtain the conditional density function π(ξ|D, S) by the transformation from
π(θ|D, S).
1.2 Obtain the proposal distribution , where  maximizes the logarithm of
π(ξ|D, S) for ξ, and  is minus the second derivative of the logarithm of π(ξ|
D, S) with respect to ξ valuated at .
1.3 Let θ0 be the current value of θ. Then ξ has a current value ξ0 log(θ0).
1.4 Generate a proposal value ξ from the proposal distribution .
1.5
Update ξ from ξ0 to ξ1 with probability , where φ is the
probability density function of a standard normal variate.
1.6 Calculate θ1 = exp(ξ1).
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Similarly, we can sample ϕ independently through the above steps 1.1–1.6 by defining ζ =
log(ϕ) and using π(ϕ|D, S).
Step 2. Given the current values of θ, ϕ and data, update the transition probabilities:
and
In step 1.2, we use the optimization program optim in the R stats package. The optimization
method is an implementation of the conjugate gradients method based on that by Fletcher
and Reeves [6]. It will also return a numerically differentiated Hessian matrix (second
derivative for a univariate case) as requested. For convergence diagnostics, we use the R
coda package. The Geweke [8] method is applied here. It is based on a test for equality of
the means of the first and last part of the samples from the Markov chain. If the samples are
drawn from the stationary distribution of the chain, the two means are expected to be equal
and Geweke's statistics has an asymptotically standard normal distribution.
4 Examples
Suppose we have the following three pathways S1, S2 and S3 suggested by KEGG. We
overlay the information collected by PrimeDB on the pathway structure. For example, we
use the (7, 3) plotted on top of the right arrow between g1 and g2 to represent there are 7
journal articles having reported that g1 activates g2 and 3 articles say the contrary, g1 inhibits
g2. The KEGG information is given in the structures and weighted graphs as shown. So the
right arrows and T (stop) arrows in the graph are suggested by KEGG. For example, in all
the pathways, KEGG suggests that g1 activates g2 as pictured here with the right arrow.
However, we only believe it with a certain degree. So we incorporate the possibility that g1
may actually inhibit g2 with a probability which may be small. So this framework would be
consistent with the PrimeDB results. We summarize the prior information from both KEGG
and PrimeDB as follows:
1. Pathway 1 (S1):
2. Pathway 2 (S2):
3. Pathway 3 (S3):
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Let us first consider the simple Bayesian model. Note the prior distribution for S1 can be
described by the product of the following five distributions: θ1 ~ βe(1, 1), θ2|1 ~ βe(7, 3),θ3|2 ~ βe(8, 1), ϕ4|1 ~ βe(3, 3) and ϕ5|4 ~ βe(9, 6). Note the PrimeDB for the g4 to g5 reaction
says (6, 9) indicating 6 journal articles reporting activation and 9 journal articles reporting
inhibition. Given ϕ5|4 is the transition probability for g4 inhibiting g5. So we construct ϕ5|4 ~βe(9, 6) from the PrimeDB. The prior distribution for S2 is the product of θ1 ~ βe(1, 1), θ2|1
~ βe(7, 3), θ3|2 ~ βe(8, 1), ϕ4|3 ~ βe(10, 1) and ϕ5|4 ~ βe(9, 6) Note that the parameters in the
beta distribution in the latter two components are in reverser order due to the inhibition
effect proposed by KEGG. Suppose we have three microarray experiments yielding the
following results ( ), ( ), ( ) for g1, . . . , g5. Then the
likelihood for the data under S1 is
. So the posterior distribution
is the joint distribution of the independent components with θ1 ~ βe(3, 2), θ2|1 ~ βe(8, 5),θ3|2 ~ βe(10, 2), ϕ4|1 ~ βe(5, 4) and ϕ5|4 ~ βe(11, 7). And, the likelihood under S2 is similar
to S1 except  is replaced by , so the posterior distribution for S2 is similar to
that of S1 except the posterior component for ϕ4|1 is replaced by ϕ4|3 ~ βe(13, 1).
On the pathway selection, we need to evaluate the symmetric KL divergence for each path.
We tabulate the activation and inhibition counts (ai|j, bi|j) from PrimeDB, and the concordant
and discordant counts (ni|j, n – ni|j), from the microarray experiments in Table 3. Use the
notation SKLi|j for the symmetric KL divergence for gene i with parent j. SKLi|j can be
easily calculated using (2.6) and (2.7).
We summarize the symmetric KL divergence for the three pathways in Table 4, and
conclude that S2 is best supported by the microarray experiments.
Figure 2 displays the discrepancy between the prior and posterior densities for each
transition probability in these three pathways. Among the comparison of the six graphs, the
prior and posterior of ϕ5|4 overlap to the largest extent. For ϕ4|3, the discrepancy mainly lies
in the tiny area underneath the peak, while the moderate difference for ϕ4|1 ranges from 0.1
to 0.8. The big piece of prior for θ3|2 protruding its posterior results in larger discrepancy
than that of θ2|1. So the order of differences shown in the figure and the ranking of SKLi|j in
Table 3 are coherent.
Now we consider the multilevel models with the same data. We first generate θ(t) and ϕ(t)
independently from  and , for t = 1, . . ., 100000. We then give the g-functions and
h-functions in three pathways. For S1, the activated gene set is . So we have
Moreover, the inhibited gene set is , so
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Observing the S2 differs from S1 only in the arc g4, which is inhibited by g3 rather by g1. So
in S2, we replace , , and h2(ϕ) with
S3 is a subgraph of S1 with g1 activating g2 and inhibiting g4. We use the corresponding g-
functions, and change  and . In addition to let μ = 1 and ν =
1, in which case transition probabilities conditional on the hyperparameters are simply the
same as those in the simple model, we vary the values of hyperparameters. The results in
Table 5 show that lowering both the values of μ and ν to 0.5 and 0.25, i.e., lessening our
prior belief on activation and inhibition effects indicated by the PrimeDB, will not alter the
ranking of the pathways. However, if we put dramatically different weights on the activation
and inhibition, the ranking may be changed. In this situation, biologists apply strong
expertise information to assign the weights.
The posterior estimates for the parameters for the simple model and the multilevel model
with μ = 1 and ν = 1 are listed in Tables 6 and 7, respectively. The results show that the two
sets of estimates of the transitional probabilities, one with the simple model and the other
with the multilevel model, are very close. Note that in the simple model, the posterior
estimates for S3 are exactly the same as their counterparts in S1.
5 Application to an Osteoblast Lineage Study
Osteoblast differentiation is regulated by a number of systemic hormones and local factors
that induce different signaling pathways in cell within the osteoprogenitor lineage. We use
four biological pathways as benchmark in the present study to test the model performance.
They include the Wnt signaling pathway, bone morphogenetic protein (BMP) signaling
pathway, a specified calcium signaling pathway, and adipocytokine signaling pathway. The
pathway structures (i.e., the molecules involved and the interactions among the molecules)
can be retrieved from literatures and public databases such as KEGG and BioCarta. Kalajzic
et al. [16] report the essential roles of the first two pathways in modulating bone mass. The
latter two pathways are considered to be biologically irrelevant to osteoprogenitor cell
differentiation. This is pointed out by other biological studies including [9, 12–15, 18, 27,
28].
We simplified the complicated pathway structures by keeping their main trunks and pruning
off most of the branches. The “stripped” versions of pathways are shown in Fig. 3.
Essentially, only key players along the signaling transduction path from the beginning
(ligand) to the end (usually transcription factor) and their direct regulators are kept. We
made this simplification for the following reasons. First, a few key players are usually
enough to determine whether a pathway is active or not. For example, in the simplest
scenario of one-experiment case, knowing the expressions levels of wnt, fzd and tcf being
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up-regulated, a biologist is inclined to predict the Wnt signaling pathway as active, whereas
the three molecules are ligand, receptor and final effecter of the pathway, respectively [16].
Superior to this judgemental call, our models not only allow synthesizing multiple
experiment outcomes but also numerically measure pathways’ activities. Second, it is not
necessarily true that all molecules in a pathway will behave consistently when it is active.
Some of them may have functions not exclusive to the pathway, and hence show no change
or even reversed change as the pathway predicts.
We validated our models through a microarray study [16] in which the mouse cavarial
cultures at day 7 and 17 underwent Affymetrix microarray analysis to understand the gene
expression patterns at distinct stages of osteoprogenitor maturation. Within a primary bone
cell culture, limited number of cells become mature osteoblasts and represent only a small
proportion of the total cell populations. Therefore, it is never certain whether the observed
gene expression changes based on a heterogenous cell mixture are associated with fully
differentiated osteoblast only or with other cell populations. To overcome this problem,
Kalajzic et al. utilized Col1a1 promoter-green fluorescent protein transgenic mouse lines to
generate more homogeneous cell populations at the preosteoblastic stage and mature
osteoblast stage. They demonstrated the importance for doing this cell separation for valid
microarray interpretation. For illustration purpose, we focused on the gene intensities in
sorted mature osteoblast only. They were taken from the cells with 2.3GFPpos and cells with
2.3GFPneg in the 17-day-old cultures. In this three-replicate data set, we first categorized the
genes in the pathways of interest as up-regulated (∪), down-regulated (∩), or equivalently
expressed (EE) if their fold changes are greater than 2, less than 1/2, or in between,
respectively. If a gene has a single activator parent, we counted the number of coherence
(denoted as nceq in Table 8) for the ordered pair (parent, child) with the outcomes to be
( ), ( ) or (EE, EE). If a gene has a single inhibitor parent, nceq is for the (parent,
child) outcomes being ( ) ( ) or (EE, EE). If a gene has odd number of multiple
parents, in each replication, we checked coherence for each individual parent related to the
child as in a single-parent case, then used majority rule to decide overall being coherent or
not. Here, nceq is the count for overall coherence for all replications. Likewise, if a gene has
even number of multiple parents and inhibitor parents are present, we used the inhibitor
outcomes only to conclude being overall coherent or not per replication. If a gene has even
number of single-type parents (i.e., all activators or all inhibitors), we either used majority
rule to decide overall coherence per replication in no ties case, or favored being coherent in
tie case.
Given the PrimeDB is still under construction, we use the KEGG database as a proxy for the
PrimeDB in this example. We queried the biological pathway information stored in KEGG
database to get the prior knowledge of the pathways. Each pairwise interaction in the
pathways was checked against all the pathways in KEGG database. For a gene with single
activator, we counted the number of pathways a, where parent–child activation interaction
exists. Parameter a is then defined as a + 0.5, the number 0.5 is added to all prior counts to
avoid improper prior caused by zero counts. We also defined parameter b from the number
of pathways where both parent and child exist but have no activation association between.
Likewise, the activation interaction was replaced with inhibition in defining a and b for
genes with single inhibitor parent. For a multiple-parent case, we defined parameter a
similarly from the number of pathways where at least one of the parents has interaction
pointing to the child, and parameter b from the number of pathways where at least one
parent exists together with the child but have no interaction between any parent– child pair.
The interaction feature between parents and child, i.e., activation or inhibition, was
determined by majority rule. All the KEGG pathway information was downloaded and
stored in a relational database, such that the prior parameters can be retrieved automatically.
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Table 8 lists the parent–child directional interaction (denoted as Dtype), the prior
parameters, number of coherence, and individual SKL score per child (skl.g) based on the
simple model for the four signaling pathways. Dtype takes value of 1, 0 and 2 to stand for
activation, inhibition and multiple-parent case, respectively. Table 9 gives the SKL scores
for the four pathways based on the simple model and multilevel model. The two signaling
pathways that play essential role in the osteoblast lineage progression, Wnt and BMP, have
smaller SKL scores than the other two pathways. In multilevel models 1–3, we set the values
of the hyperparameters that govern our belief on the prior counts acquired from KEGG, at
all equal to 1, 2 or 0.5. The ranking of the pathways is not sensitive to the choice values of
hyperparameters.
It is worthwhile noting that the above extension to multiple parents does not seem to follow
along the line of a Bayesian network. It is possible to have the usual Bayesian network
extension to construct conditional distribution given multiple parental nodes. However, lack
of prior information from the literature search in practice has made us resolve to a more
realistic approach, as presented here.
6 Discussion
We have proposed a novel methodology to integrate the high-throughput data, pathway
structure and medical literature regarding the gene-gene directional interactions (PrimeDB).
We construct BN from a pathway database, and use PrimeDB to guide the choices of prior
parameters or hyperparameters in the BN. Then we show how to update these information
using high-throughput genomics experiments. Our method numerically measures the
strength of agreement between each pathway and the experiment using the symmetric
Kullback Leibler measure incorporating the activation/inhibition association permeated in
the biomedical literature. So we can rank the importance of these pathways in terms of their
relatedness to the biological experiments to gain further knowledge in system biology. When
a pathway agrees with the experimental data structurally, we would expect the pathway has
a small SKL divergence measure. However, this cannot be guaranteed if the prior belief is
terrible. So our method also relies on good choices of the prior distribution that should be
flat and has huge support. In the illustration using real data, we have chosen the KEGG
pathway database as the primary source of pathway structure and its gene-gene interaction
as representative of medical journal counts (PrimeDB). The result might rely on the extant
knowledge from a single data repository. However, our methodology is general enough that
can be applied to any good databases that include gene-gene direction relationships as a
substitute of the PrimeDB.
When a pathway is identified, it suggests the pathway is most agreeable with the data
presented. On the other hand, the pathway with the highest K–L divergence suggests the
pathway structure is not well supported by the data. This may be caused by (1) unexpected
data, (2) dubious pathway structure, or both. So it has potential to provide more insights into
the pathways.
We have used small sample size in our simulated and real examples, primarily small sample
size is common in microarray experiments. Nevertheless, our method can handle any sample
size as well. Microarray techniques are known to be noisy for biologists, so their results are
often questioned by the biologists. Small sample exacerbates this situation. So incorporating
a Bayesian frame work and borrowing information from the literature will add credibility to
the microarray studies. Moreover, the multilevel model provides a more robust framework
for sharing information among similar genes in evaluating the pathways.
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Our method can handle large networks quite efficiently. It first computes the SKL score for
each gene independently, then takes their averages as the pathway SKL score. In the simple
model, the gene-specific SKL score reduces to a linear function of digamma functions. It
hence can readily handle large pathways at fast speed. For the multilevel model, we use a
collapsing technique and as a result sample from the prior distribution only instead of from
both prior and posterior distributions of θ and ϕ, the two parameters that govern prior belief
of the literature count. This greatly improves the efficiency in the numerical evaluation of
the integrals in I2′ and I3′, the sums of the SKL scores for activated genes and inhibited
genes. R programs have been developed based on this method. In the osteoblast lineage
study, the four pathways have 11, 12, 9 and 10 genes, respectively. It takes less than 13
seconds in total to compute their SKL scores of the multilevel model using R 2.13.0 on a
laptop computer with 2nd generation Intel Core i5-2410M processor 2.30 GHz. So it should
not be a burden to compute SKL for large pathways which consist of about a hundred nodes
at most as shown in KEGG.
Starting with the gene expression data from microarray, we first applied some statistical
tests to classify the genes as up-regulated, down-regulated, or equivalently expressed. Fold
change was used in our real data analysis. Then we construct Bayesian network for each
pathway. So our study applies to the continuous gene expressions. However, we simplify the
agreement assessment by discretizing the data. It would be interesting to extend our method
to directly using the continuous gene expression. Nevertheless, we do not think the
extension will be straightforward especially on a realistic prior construction.
We think the strength of this paper is on its ability to handle directed graphs with directed
prior information on gene functions. On the other hand, our method can be modified to
handle undirected graphs. In that, we will not differentiate activation or inhibition direction,
change all of them into connection, then our method with reduced parameters can handle the
undirected graph. For mixed graphs with directed and undirected edges, we need to add the
connected part for the direction-unknown edges, then we can handle them similarly.
In this paper, we also assume that microarray outcomes are available for all the genes
considered in the pathway (BN). However, it is often in practice so, that the pathway
includes genes that microarray may not explore. So this falls into the missing data problem
in BN. Conditional inference with incomplete data and model selection can still be carried
out using Expectation and Maximization (EM) algorithm or MCMC. Further investigation
on this issue should be worthwhile.
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Fig. 1.
Flowgram of data sets integration
Zhao et al. Page 23
Stat Biosci. Author manuscript; available in PMC 2013 March 09.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 2.
Prior and posterior densities for transition probabilities
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Fig. 3.
Four simplified signaling pathways
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Table 1
Transition probabilities for gj to activate gi
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Table 2
Transition probabilities for gj to inhibit gi
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Table 4
Pathway selection based on the simple model
Pathway SKL(S)
S 1 ⅕(SKL1 + SKL2|1 + SKL3|2 + SKL4|1 + SKL5|4) = 0.4049
S 2 ⅕(SKL1 + SKL2|1 + SKL3|2 + SKL4|3 + SKL5|4) = 0.3794
S 3 ⅓(SKL1 + SKL2|1 + SKL3|2) = 0.4777
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Table 9
SKL(S) of the four pathways
Pathways Simple Model Multilevel Model1 Multilevel Model2 Multilevel Model3
Wnt 1.0922 1.0673 1.1565 0.9828
Bmp 1.3916 1.2471 1.4976 1.0197
Calcium 1.8263 1.7778 2.0835 1.4889
Adipocytokine 1.7081 1.4572 1.7602 1.1823
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